text:
Please note that the Glossary is currently under revision.
Adverse Drug Reaction (ADR)In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established, all noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. The phrase "responses to a medicinal product" means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility, i.e. the relationship cannot be ruled out. (ICH E6)
Adverse Event (AE)Any untoward or unfavorable medical occurrence in a human subject, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject's participation in the research, whether or not considered related to the subject's participation in the research. (OHRP) See Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events (PDF)
AdvocateAn individual who has the background and experience to act in, and agrees to act in, the best interests of the child throughout the duration of the child's participation in the research and who is not associated in any way (except in the role as an advocate or member of the IRB/EC) with the research, the investigator(s), or the guardian organization. The advocate is in addition to any other individual acting on behalf of the child as guardian or in loco parentis. (45 CFR §46.409(b) & 21 CFR §50.56(b))
AllegationA disclosure of possible research misconduct through any means of communication. The disclosure may be by written or oral statement or other communications. (ORI)
AssentA child's affirmative agreement to participate in research. Mere failure to object should not, absent of affirmative agreement, be construed as assent. (45 CFR §46.402(b) and 21 CFR §50.3(n))
AuditIndependent on-site quality assurance of monitoring performed at clinical research sites (including pharmacies and laboratories). Auditors must be fully distinct and independent from entities providing site monitoring services. (DAIDS)
AwardeeThe institution receiving a grant, cooperative agreement, or contract that assumes legal, financial, and scientific responsibility for the funds and research. (DAIDS)
back to top
Basic Sciences Program (BSP)The BSP is a program within DAIDS that focuses on the fields of pathogenesis, basic virology, immunobiology, and the discovery of novel therapeutic approaches, efficacy evaluation in lentivirus animal models, and epidemiology. (DAIDS)
Biological productAny virus, therapeutic serum, toxin, antitoxin, or analogous product available to prevent, treat or cure diseases or injuries in man. The terms "biological product" or "biologic" are deemed to be synonymous within DAIDS policies. (DAIDS)
Case historyA detailed account of relevant information gathered about a subject. This information includes the case report forms and supporting data including, for example, signed and dated consent forms and medical records, including, for example, progress notes of the physician, the individual's hospital chart(s), and the nurses' notes, as required for both IND and IDE clinical trials. (21 CFR 312.62(b) & 21 CFR §812.140(a)(3) )
Central Data Management FacilityThe group responsible for managing the database and handling and processing the data gathered during a clinical trial. The location can be the same as the data collection site. (DAIDS)
ChildrenPersons who have not attained the legal age for consent to treatments or procedures involved in research, under the applicable law of the jurisdiction in which the research will be conducted. (45 CFR §46.402(a) and 21 CFR §50.3(o))
Clinical InvestigationAny experiment that involves a test article and one or more human subjects, and that either must meet the requirements for prior submission to the FDA...or the results of which are intended to be later submitted to, or held for inspection by, the FDA as part of an application for a research or marketing permit. FDA has defined "clinical investigation" to be synonymous with "research". (FDA)
Clinical investigatorA qualified professional that conducts clinical research activities including: collaboration and information exchange with community representatives; recruitment; enrollment; protocol visit conduct; management of study products; assessment and reporting of critical events; collection and management of clinical research data; communication of data; and creation, maintenance and storage of research records including participant files, source documents, regulatory files, subject identification information, clinical reports, and case report forms. (DAIDS)
Clinical Quality Management Plan (cQMP)A formal written document that defines the processes and procedures that guide quality management activities (including Quality Assurance and Quality Control) in the clinical setting and details the responsibility, scope, and frequency of these activities. (DAIDS)
Clinical researchResearch conducted on participants, material, or data of human origin with an identifiable person as the source. Clinical research includes exploratory, behavioral, and observational studies. All clinical trials are a subset of clinical research (DAIDS).
Clinical research recordsThe records that describe or record the methods, conduct, and/or results of a clinical trial, and the actions taken. Examples of these documents may include, but are not limited to, all essential and source documents listed in the DAIDS Policy on Essential Documents Appendix. The records may be in any form, including written, electronic, magnetic, and optical records; and scans, x-rays, and electrocardiograms. Clinical research records include case histories and source documents. (DAIDS)
Clinical research siteDiscrete locations (e.g., hospitals, outpatient clinics, health maintenance organizations, community health centers, private practices, clinics) supported and/or sponsored by NIAID (DAIDS) where qualified professionals conduct clinical research in accordance with Good Clinical Practice and applicable regulations. (DAIDS)
Clinical Research Site (CRS) LeaderThe onsite senior research scientist responsible for the administrative and scientific components of the CRS. The CRS leader is responsible for overall site activities, including day-to-day operations, performance, and compliance at the site level. (DAIDS)
Clinical Sciences Review Committee (CSRC)The Division of AIDS internal scientific review committee responsible for the programmatic review of therapeutic protocols sponsored by DAIDS. The review will include careful assessment of the scientific objectives, design, safety, ethics, and feasibility of proposed research protocols. Scientific representatives from collaborating NIH Institutes and Centers participate as appropriate. (DAIDS)
Clinical Site Monitoring Group (CSMG)The group delegated by DAIDS to conduct periodic on-site monitoring visits to DAIDS Clinical Trial Units to evaluate the quality and validity of study data, compliance with Good Clinical Practices, and protection of research subjects. Reports findings to DAIDS. (DAIDS)
Clinical TrialA prospective study of human subjects designed to answer questions about biomedical or behavioral interventions, e.g., drugs, treatments, devices, or new ways of using known treatments to determine whether they are safe and effective. (NIAID)
Clinical Trials Agreements (CTAS)An agreement negotiated between DAIDS and a pharmaceutical collaborator providing an investigational agent for a Network study and DAIDS (as the study sponsor). Describes CTA's respective responsibilities and rights includes IND sponsorship, safety and data monitoring, and access to data. (DAIDS)
Clinical Trial Unit (CTU)Clinical Trials Unit (CTU) is an entity composed of an administrative component and one or more Clinical Research Sites that contribute to the Network clinical research plan by conducting the clinical research (that is, executing clinical protocols). A CTU may also contribute scientific and clinical research expertise to the development of the Network clinical research plan. A CTU is responsible for developing and maintaining effective community relationships; enabling community participation in Clinical Research Sites, CTU, and Network activities; and ensuring that all clinical research is conducted in compliance with Network bylaws, policies and procedures, DAIDS policy and procedures, Federal regulations, and any applicable local requirements. (DAIDS)
Code of Federal Regulations (CFR)The codification of the general and permanent rules published in the US Federal Register by the executive departments and agencies of the US federal government. It is divided into 50 titles that represent broad areas subject to US federal regulation. Each volume of the CFR is updated once each calendar year and is issued on a quarterly basis. (NIH)
Community Advisory Board (CAB)Community Advisory Board (CAB) is an active group representing the local population(s) impacted by HIV/AIDS. CAB members work in close communication with CTU investigators and staff to include the local perspective in the implementation of the HIV/AIDS clinical research plan. (DAIDS)
Completion of a clinical research studyOccurs when the following activities are finished:
Conflict of Interest (COI)A situation when someone has or is perceived to have competing professional obligations or personal or financial interests that would make it difficult to fulfill his duties fairly. (DAIDS)
Continuing noncomplianceA pattern of actions or omissions to act that suggests a future likelihood of reoccurrence and indicates an inability or unwillingness to comply with applicable regulations, laws or the requirements or determinations of the IRB/EC. (DAIDS)
Critical eventAny unanticipated study-related incident that causes or increases the risk of harm to participants or others or has a significant adverse impact on study outcomes or integrity. A single incident that is determined to be a critical event may represent more than one class of critical event. (DAIDS)
CTU Administrative UnitThis CTU component provides oversight of the grantee award. Each CTU must have an administrative structure that resides within the Awardee institution. It is not a requirement that this component function as a clinical trial site. (DAIDS)
CTU Principal InvestigatorThe Principal Investigator is listed as the Grantee on the Notice of Award and is responsible for all CTU activities and CTU performance. This includes responsibility for affiliated clinical research sites (CRS), including communications, site performance and financial management. The principal investigator also provides CTU scientific and administrative representation to the Network(s).
Data and Safety Monitoring Board (DSMB)The DSMB is an independent panel of experts established by NIAID and charged with the responsibility of monitoring the progress of trials, the safety of participants, and the efficacy of treatments being tested. The DSMB also makes recommendations to NIAID concerning continuation, termination or modification of the studies based on observed beneficial or adverse effects of any of the interventions under study. This panel is funded separately by NIAID. (DAIDS)
Data Collection SiteThe location where clinical trial data is collected and case report forms are completed (usually the trial site). (DAIDS)
Division of AIDS (DAIDS)The Division within the NIAID that has the primary responsibility for basic and clinical research on HIV/AIDS. (DAIDS)
DAIDS fundedNIAID (DAIDS) is providing financial support for the clinical trial or study. (DAIDS)
DAIDS Protocol Registration Office (PRO)An office within the DAIDS Regulatory Support Contract (RSC) that receives and processes all protocol registration materials for DAIDS. (DAIDS)
DAIDS RSC Safety OfficeThe Office contracted to receive Expedited Adverse Event reports that are submitted to DAIDS. (DAIDS)
Division of AIDS (DAIDS) Safety OfficeThe Office to which adverse events requiring expedited reporting are submitted. Currently located in the Regulatory Affairs Branch (RAB) support contract and managed through RAB. (DAIDS)
DAIDS Regulatory Support Center (RSC)A contract that provides clinical, regulatory, and technical support services for NIAID (DAIDS)-supported and -sponsored clinical trials. (DAIDS)
DAIDS sponsoredNIAID (DAIDS) is responsible for the management (including submission of the Investigational New Drug Application (IND) to the Food and Drug Administration (FDA) and the initiation of the study) and oversight for the clinical trial or study. (DAIDS)
DAIDS supportedClinical research activities would be considered to be supported by NIAID (DAIDS) under one or more of the following circumstances:
DAIDS Tables for Grading Adult and Pedicatric Adverse Experiences (Toxicity Tables)Lists of common terms and severity (intensity) parameters used to describe adverse events occurring in DAIDS-sponsored clinical studies/trials. (DAIDS)
DrugArticle intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals.(FDA)
EAE FormThe Expedited Adverse Event (EAE) paper form to be completed if DAERS system is not available. (DAIDS)
Essential DocumentsDocuments that individually and collectively permit evaluation of the conduct of a study and the quality of the data produced. (ICH E6)
EAE Reporting DaysThe days that count toward the 3-day timeline provided for reporting of EAEs to DAIDS. See DAIDS EAE Reporting manual for criteria used to determine reporting days. (DAIDS)
Expedited adverse event (EAE)An adverse event that meets the criteria for expedited reporting, as specified in the applicable DAIDS manual. (DAIDS)
FabricationMaking up data or results and recording or reporting them. (ORI)
FalsificationManipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record. (ORI)
Federalwide Assurance (FWA)Federalwide Assurance (FWA) is the only type of assurance of compliance accepted and approved by the Office for Human Research Protections (OHRP) for institutions engaged in non-exempt human subjects research conducted or supported by the U.S. Department of Health and Human Services (HHS). Under an FWA, an institution commits to HHS that it will comply with the requirements set forth in 45 CFR 46, as well as the Terms of Assurance. (See Federalwide Assurance (FWA) for the Protection of Human Subjects.)
Form FDA 1572FDA required document in which clinical investigators agree to conduct the clinical trials according to Federal Regulations. The Form FDA 1572 is signed and submitted to the IND sponsor. (DAIDS)
Full Regulatory ReviewThe final review of the protocol, including the sample informed consent(s), by the Regulatory Affairs Branch (RAB) prior to medical officer sign off and distribution to the sites. (DAIDS)
GuardianAn individual who is authorized to consent on behalf of a child to general medical care under applicable local law where the research is being conducted. (45 CFR §46.402(e))
For clinical trials conducted under FDA regulations, a guardian is an individual who is authorized to consent on behalf of a child to general medical care when general medical care includes participation in research under the applicable local law where the research is being conducted. A guardian is also an individual who is authorized to consent on behalf of a child to participate in research. (21 CFR §50.3(s))
Good Clinical Practice (GCP)An international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects. (ICH E6)
Independent Safety MonitorThe physician or other appropriate expert who is independent of the study and available to review SAEs and other safety data in a timely fashion and recommends appropriate actions to the study team and the National Institutes of Allergy and Infectious Diseases (NIAID). (DAIDS)
Informed Consent Form (ICF)A document that provides the elements of informed consent as found in 21 CFR 50.25 and 45 CFR 46.116 (DAIDS)
Informed Consent ProcessA process by which a participant voluntarily confirms his or her willingness to participate in a particular study after having been informed of all aspects of the trial that are relevant to the participant's decision to participate. (ICH E6)
Institutional Review Board/Ethics Committee (IRB/EC)The board, committee, or other group formally designated by an institution to review, to approve the initiation of, and to conduct periodic review of research involving human subjects. The primary purpose of such review is to assure the protection of the rights and welfare of participants in research. IRB/EC reviewing DHHS sponsored research must be registered with OHRP and identified on the institute FWA. (DAIDS)
Institutional Review Board/ Ethics Committee (IRB/EC) recordsThe documentation maintained by the institution, or when appropriate, an IRB/EC, of IRB/EC activities, as required by HHS 45 CFR §§46.103(b)(3-5) and §46.115
International Conference on Harmonisation (ICH) GuidelinesDeveloped, through a collaboration between the FDA and regulatory agencies in Japan and the European Union, to "harmonize" regulatory requirements to produce marketing applications acceptable to the United States, Japan, and the countries of the European Union. (DAIDS)
Investigational Device Exemption (IDE)Similar to an IND, allows an unapproved medical device to be used for investigational purposes. For more information, go to 21 CFR Part 812 and NIAID Human Subjects Resources portal. (NIAID)
Investigational New Drug (IND)A drug or biological product that is used in a clinical investigation. The terms "investigational new drug" and "investigational drug" are deemed to be synonymous within DAIDS policies. (DAIDS)
Investigational New Drug Application (IND)A request for authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans. Such authorization must be secured prior to interstate shipment and administration of any new drug or biological product that is not the subject of an approved New Drug Application or Biologics/Product License Application. (FDA) Application required by the US FDA before clinical trials of an investigational drug or biological agent may be initiated. An IND is also required if the US FDA has not approved the route of administration, dosage level, or patient population for the drug or biological agent. (DAIDS)
Investigator INDAn IND submitted by an physician who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed. (DAIDS)
Investigator of Record (IoR)The individual at the CRS responsible for ensuring that a clinical trial is conducted in accordance with the protocol, applicable U.S. federal regulations, in-country regulations and any provisions imposed by the reviewing IRB/EC/other regulatory entity. This person is the signatory for the Form FDA 1572 for studies conducted under an IND or the DAIDS Investigator of Record Agreement for non-IND studies. (DAIDS)
Investigator of Record (IoR) AgreementA document required by DAIDS for Non-IND studies. The IoR is required to sign and date this document accepting full responsibility for the conduct of the trial at their CRS.(DAIDS)
Key PersonnelIndividuals who are involved in the design and conduct of NIH-funded human subjects' clinical research. This includes all individuals named on the Form FDA 1572 or DAIDS Investigator of Record Agreement and any clinical research site personnel who have more than minimal involvement with the conduct of the research (performing study evaluations or procedures or providing intervention) or more than minimal study conduct-related contact with study subjects or confidential study data, records, or specimens. (NIH)
LabelThe FDA approved label is the official description of a drug product which includes indication (what the drug is used for); who should take it; adverse events (side effects); instructions for uses in pregnancy, children, and other populations; and safety information for the patient. Labels are often found inside drug product packaging. (ICH E6)
Legally marketed productA product that received licensure or approval for marketing in the United States (U.S.) (FDA)
Medical OfficersA DAIDS staff member or member from another sponsoring Institute or Centers that monitors the safety and efficacy of the intervention(s) for ongoing studies and those in development. (DAIDS)
Minimal RiskThe probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. (45 CFR §46.102(i) and 21 CFR §50.3(k))
MonitorsIndividuals qualified by education or experience, whose primary role is to ensure compliance with the applicable regulations, policies, and standard procedures, as well as compliance with the study protocol as approved by the institutional review board or research ethics board. (DAIDS)
DAIDS MonitorA monitor who is contracted by DAIDS. (DAIDS)
External Non-DAIDS MonitorA qualified monitor not contracted by DAIDS and not employed or supervised by the study investigators, network, or site, has no affiliation with any of the participating clinical research sites, and has no role in trial conduct except as a site monitor. The monitor must be contracted or supplied by an organization (i.e. pharmaceutical sponsor, CRO, or academic institution) that conducts independent clinical site monitoring utilizing its own monitoring and reporting SOPs and having a distinct and independent supervisory structure for monitoring services. (DAIDS)
Internal Non-DAIDS MonitorA qualified employee of a network involved with conduct of the clinical trial having no affiliation with any of the participating clinical research sites and not involved with the conduct of the trial at any participating clinical research site except for his/her role as a monitor. (DAIDS)
DAIDS MonitorA monitor who is contracted by DAIDS. (DAIDS)
External Non-DAIDS MonitorA qualified monitor not contracted by DAIDS and not employed or supervised by the study investigators, network, or site, has no affiliation with any of the participating clinical research sites, and has no role in trial conduct except as a site monitor. The monitor must be contracted or supplied by an organization (i.e. pharmaceutical sponsor, CRO, or academic institution) that conducts independent clinical site monitoring utilizing its own monitoring and reporting SOPs and having a distinct and independent supervisory structure for monitoring services. (DAIDS)
Internal Non-DAIDS MonitorA qualified employee of a network involved with conduct of the clinical trial having no affiliation with any of the participating clinical research sites and not involved with the conduct of the trial at any participating clinical research site except for his/her role as a monitor. (DAIDS)
Notice of Grant Award (NGA)The legally binding document that notifies the grantee and others that an award has been made. It contains or references all terms and conditions of the award, and documents the obligation of US federal funds. (NIH)
Observational StudyA type of study in which individuals are observed or certain outcomes are measured, but no treatments or interventions are assigned by the study. (DAIDS)
Office for Policy in Clinical Research Operations (OPCRO)An office in the Division of AIDS (DAIDS) that provides a variety of clinical research management resources and oversight to DAIDS clinical research portfolio. This includes overseeing the development, standardization, implementation and execution of policies, procedures and standards of conduct for all of DAIDS domestic and international clinical research. (DAIDS)
ParentThe child's biological or adoptive parent.( 45 CFR §46.402(d) and 21 CFR §50.3(p))
ParticipantA living individual about whom an investigator conducting research obtains:
(1) Data through intervention or interaction with the individual, or(2) Identifiable private information. (45 CFR 46).
The terms "participant " and "subject" are deemed to be synonymous within DAIDS policies. (DAIDS)
PermissionThe agreement of parent(s) or guardian to the participation of their child or ward in research. (45 CFR §46.402(c) and 21 CFR §50.3(r))
Pharmacist of RecordA licensed/registered pharmacist who performs the day to day pharmacy activities and study product management including but not limited to the procurement, storage, preparation, dispensing and final disposition of study products for DAIDS sponsored or funded clinical research trial(s) must be identified as the Pharmacist of Record. (DAIDS)
PharmacyAny facility, building, or room used to perform one or more of the following functions: storage, preparation, dispensing, management of study products, (example: dispensary, drug storage unit, drug store). (DAIDS)
Pharmacy Ancillary SuppliesAny materials or tools that may be used in a pharmacy to perform and support the day to day activities and functions of the pharmacist, such as needles and syringes, oral syringes, prescription vials and lids, gowns, masks, IV solutions, diluents. (DAIDS)
Pharmacy EquipmentApparatus (device or machinery) that is utilized to ensure the physical and scientific integrity of the study product during shipment, storage, handling, and preparation. Examples of pharmacy equipment are; biological safety cabinets, refrigerators, -20 C freezers, -70 C freezers, air conditioners, dehumidifiers, thermometers, vortex machines, temperature alarm systems, limited access/security systems (alarms, key lock) in study product and pharmacy regulatory file storage areas, locking file and storage cabinets, shelving, counting trays for tablets and capsules, graduated cylinders, spatulas, study product containers, fax machines, computers, and printers. (ICH E6)
PlagiarismUsing another person's ideas, processes, results, or words as one's own without giving credit. (ORI)
Possibly related to the researchThere is a reasonable possibility that the adverse event, incident, experience or outcome may have been caused by the procedures involved in the research. (OHRP)
Principal Investigator (PI)The qualified person designated by the applicant institution to direct the funded research program. PIs oversee the scientific and technical aspects of an award and the day-to-day management of the research. (DAIDS)
ProtocolA document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. (ICH E6)
Protocol AmendmentA written description of a change(s) to or formal clarification of a protocol. (ICH E6)
Protocol RegistrationThe process established by DAIDS to ensure that all sites participating in NIAID (DAIDS)-supported and/or -sponsored clinical research that is reviewed by a DAIDS Scientific Review Committee conduct the research in accordance with requirements for human subjects protection and the use of investigational new drugs (where applicable). The process includes initial protocol registration, amendment registration, continuing review documentation, deregistration and submission of other required documents. (DAIDS)
Protocol Registration SubmissionsThe most common types of submissions that a CRS may send to the DAIDS Protocol Registration Office (PRO) include the following:
Protocol Registration Team (PRT)A Team within OPCRO responsible for managing the PR System, which includes oversight of the DAIDS PRO. (DAIDS)
Prevention Sciences Review Committee (PSRC)The Division of AIDS internal scientific review committee responsible for the programmatic review of vaccine and prevention protocols sponsored by DAIDS. The review will include careful assessment of the scientific objectives, design, safety, ethics, and feasibility of proposed research protocols. Scientific representatives from collaborating NIH Institutes and Centers participate as appropriate. (DAIDS)
Protocol TeamA team of individuals comprised of grantees, investigators, statisticians, and other protocol support personnel who work to develop concepts into NIAID (DAIDS)-funded and/or -sponsored research studies. DAIDS medical officers may be involved as members of this team. (DAIDS)
Quality Assurance (QA)A periodic, systematic, objective and comprehensive examination of the total work effort to determine the level of compliance with accepted Good Clinical Practice (GCP) standards. For example, a monthly peer review of source documents compared to CRF pages to determine adherence to protocol requirements. (DAIDS)
Quality Control (QC)The real time, on-going ("day-to-day") observation and documentation of a site's work processes to ensure that accepted procedures are being followed. For example, reviewing demographic information for accuracy on each Case Report Form (CRFs) page prior to entry into the database. (DAIDS)
Quality ManagementThe overall psystem that includes all activities involved in Quality Assurance and Quality Control including the assignment of roles and responsibilities, the reporting of results and the resolution of issues identified during the review. (DAIDS)
Regulatory Affairs Branch (RAB)A branch of DAIDS within the Office of Clinical Research Policy and Resources (OPCRO). RAB performs regulatory surveillance over clinical trials sponsored/funded by DAIDS. (DAIDS)
Research misconductFabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results. Research misconduct does not include honest error or differences of opinion. (42 CFR §93.103)
Research misconduct records include records related to investigations of research misconduct and records of research misconduct proceedings
Records related to investigations of research misconduct: The records containing data or results that embody the facts resulting from scientific inquiry. These include research proposals, laboratory records, physical and electronic, progress reports, abstracts, theses, oral presentations, internal reports, journal articles, and any documents and materials provided to HHS or an institutional official by a respondent in the course of the research misconduct proceeding. (42 CRF §93.224)
Records of research misconduct proceedings: Records showing the actions that an institution has taken related to alleged research misconduct. (42 CFR §93.223) Examples of these records include the records that the institution secures for the research misconduct proceedings, except for duplicate records; the documentation of the determination of irrelevant or duplicate records; the inquiry report and final documents produced in the course of preparing that report, including documentation of any decision not to investigate; the investigation report and all records in support of that report, including the recordings or transcriptions on each interview conducted. (42 CRF §93.317(a))
Records related to investigations of research misconduct: The records containing data or results that embody the facts resulting from scientific inquiry. These include research proposals, laboratory records, physical and electronic, progress reports, abstracts, theses, oral presentations, internal reports, journal articles, and any documents and materials provided to HHS or an institutional official by a respondent in the course of the research misconduct proceeding. (42 CRF §93.224)
Records of research misconduct proceedings: Records showing the actions that an institution has taken related to alleged research misconduct. (42 CFR §93.223) Examples of these records include the records that the institution secures for the research misconduct proceedings, except for duplicate records; the documentation of the determination of irrelevant or duplicate records; the inquiry report and final documents produced in the course of preparing that report, including documentation of any decision not to investigate; the investigation report and all records in support of that report, including the recordings or transcriptions on each interview conducted. (42 CRF §93.317(a))
Safety Monitoring Committee (SMC)An independent group of experts that advises NIAID and the study investigators for some Phase I and most Phase II trials. The primary responsibility of the SMC is to monitor participant safety. (DAIDS)
Sample Informed Consent (SIC)An informed consent developed by the protocol team for a specific protocol that will help guide participating sites in the development of their site specific informed consent. (DAIDS)
Serious Adverse Drug ExperienceAny adverse drug experience occurring at any dose that results in any of the following outcomes: Death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent on of the outcomes listed in this definition. (21 CFR 312)
Serious noncomplianceAn event that occurs within the context of the research that meets the following criteria:
Scientific Review Committee (SRC)A reviewing body within DAIDS to review the concepts and protocols developed by various programs within DAIDS (e.g., CSRC and PSRC).(DAIDS)
Serious Adverse Event (SAE)Any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. This includes important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of the outcomes listed in the definition above. (ICH E6 and E2A)
A licensed/registered pharmacist who performs the day to day pharmacy activities and study product management including but not limited to the procurement, storage, preparation, dispensing and final disposition of study products for DAIDS-supported and/or -sponsored clinical trial(s) must be identified as the Site Pharmacist. (DAIDS)
Site Specific Informed ConsentAn informed consent developed by a participating site based upon the sample informed consent which is reviewed and approved by the site's designated IRB/IEC and is used to consent subjects at the site for a specific clinical trial. (DAIDS)
Source DataAll information in original records and certified copies of original records of clinical findings, observations, or other activities in a study necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents (original records or certified copies). (ICH E6)
Source documentsThe original documents, data, and records containing clinical findings, observations, or other activities in a clinical research study that allows the reconstruction and evaluation of the study. Examples of source documents include: hospital records, clinical and office charts, laboratory notes, memoranda, subjects' diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at medico-technical departments involved in the clinical trial. (ICH E6 §1.51 and 1.52)
SponsorA person (individual, corporation or agency) who initiates a clinical investigation, but who does not actually conduct the investigation. That is the test articles is administered or dispensed to or used involving, a subject under the immediate direction of another individual. A person other than an individual (e.g. corporation or agency) that uses one or more of its own employees to conduct a clinical investigation it has initiated is considered to be a sponsor, and the employees are considered to be investigators. (FDA)
Sponsor-InvestigatorAn individual who both initiates and actually conducts, alone or with others, a clinical investigation. For example, under whose immediate direction the test article is administered, dispensed to, or used involving a subject and who also submitted the IND. (FDA)
Standard Operating Procedures (SOPS)Written procedures designed to ensure data and analysis quality by requiring uniform performance of specific functions by the group(s) that fall within their scope. An SOP is designed to provide a high level overview of tasks or functions performed. An SOP, by definition, must be followed unless a documented exception is approved. (DAIDS)
Study ProductsAny drug, biologic, vaccine, radiopharmaceutical, item or device that are either provided for the study or identified in the protocol as being a study product. (DAIDS)
SubjectA living individual about whom an investigator conducting research obtains:
(1) Data through intervention or interaction with the individual, or(2) Identifiable private information. (45 CFR 46)
For research conducted under U.S. FDA regulations, a subject is an individual who is or becomes a participant in research, either as a recipient of the test article or as a control. A subject may be either a healthy individual or a patient. (21 CFR 56)
(1) Data through intervention or interaction with the individual, or(2) Identifiable private information. (45 CFR 46)
For research conducted under U.S. FDA regulations, a subject is an individual who is or becomes a participant in research, either as a recipient of the test article or as a control. A subject may be either a healthy individual or a patient. (21 CFR 56)
The terms " participant " and "subject" are deemed to be synonymous within DAIDS policies. (DAIDS)
Suspected Unexpected Serious Adverse Reaction (SUSAR)A SUSAR is an event that is:
Suspension of IRB approvalAn IRB/EC action to temporarily withdraw approval for a study, which results in stopping some or all of the research-related activities for the study. (DAIDS)
Termination of IRB approvalAn IRB/EC action to permanently withdraw approval for a study which results in stopping the research and all research-related activities for the study. (DAIDS)
Tentative Drug ApprovalIf a generic drug product is ready for approval before the expiration of any patents or exclusivities accorded to the reference list drug product (an approved drug product to which new generic versions are compared), FDA issues a tentative approval letter to the applicant. The tentative approval letter details the circumstances associated with the tentative approval. FDA delays final approval of the generic drug product until all patent or exclusivity issues have been resolved. A tentative approval does not allow the applicant to market the generic drug product in the United States. (DAIDS)
Therapeutics Research Program (TRP)The TRP is a program within the DAIDS that is responsible for the scientific, administrative, and operational management of the clinical therapeutic research programs funded by the Division. (DAIDS)
Unanticipated ProblemsEvents that must be reported to Office of Human Research Protections (a) unanticipated problems involving risks to subjects or others or (b) any serious or continuing noncompliance with policy requirements or determinations of the IRB and (c) any suspension or termination of IRB approval. (OHRP)
Unanticipated problems involving risk to subjects or othersAny adverse event occurring in one or more subjects in a research protocol, the nature, severity, or frequency of which is not consistent with either:
Unexpected adverse eventAny adverse event occurring in one or more subjects in a research protocol, the nature, severity, or frequency of which is not consistent with either:
Unexpected Adverse Drug ExperienceAny adverse drug experience, the specificity or severity of which is not consistent with the current investigator brochure; or, if an investigator brochure is not required or available, the specificity or severity of which is not consistent with the risk information described in the general investigational plan or elsewhere in the current application, as amended. (21 CFR 312)
U. S. Food and Drug Administration (FDA)A public health agency within the United States Department of Health and Human Services. FDA's mission is to promote and protect public health by helping safe and effective products reach the market in a timely way and monitoring of products for continued safety after they are in use as authorized by The Federal Food and Cosmetic Act. The Agency regulates all clinical investigations in support of marketing applications. (DAIDS)
Vaccine and Prevention Research Program (VPRP)The VPRP is a program within the DAIDS that supports the discovery and development of vaccines and other biomedical and behavioral interventions to prevent AIDS. (DAIDS)
WardA child who is placed in the legal custody of the State or other agency, institution, or entity, consistent with applicable Federal, State, or local law. (21 CFR 50.3(q))
Last Updated April 15, 2014


text:
ARLINGTON, Wash. (AP) -- A suspect has been found dead after authorities say a shooter in woods north of the Seattle area fired at SWAT team and other police officers.
Officers were responding to reports that a man had been shot in the leg in his driveway.
Snohomish County Sheriff's spokeswoman Shari Ireton said late Sunday that the male suspect was deceased and a weapon was recovered. No other details were immediately available.
She said authorities continued to search for a possible second suspect.
The man who was shot in his driveway about 1:30 p.m. called authorities before he was taken to a hospital with a non-life threatening injury.
There were no reports of other injuries.

subset: commoncrawl


text: Use the self-timer Don't forget to get into some of the pictures yourself. Set your camera on a flat surface or a tripod. Check what you're aiming at in the viewfinder, then set the camera's self-timer so you can join the scene after you press the shutter button. Read your camera manual for detailed instructions on the self-timer.


text:
- Forza Italia!
- Currently Unavailable
Free-kick maestro Andrea Pirlo was on Italy's 2006 World Cup winning squad. Pirlo was named Man of the Match in three of those World Cup games. Cheer Pirlo on in 2010 in his official Italy home jersey.
Support the blues of the Italian national team with this official Italia Home Jersey from PUMA! This jersey uses USP moisture management technology and has the Italian national team badge heat-transferred over the left chest and the PUMA cat logo applied over the right. The PUMA cat logo is also applied to both sleeves.
100% polyester Imported.
Lamentamos que todavia no hay descripción en español para este producto.


text:
SEATTLE -- Craig Gentry instantly felt differently about being a member of the A's on Saturday.
It happened when he got word Saturday that he officially was coming off the disabled list. To make room on the roster for Gentry, the A's put outfielder Sam Fuld on the designated for assignment list.
``It feels good, and I'm excited,'' Gentry said. ``It's been a long wait. But to be part of the team finally, that's special.''
Gentry said it's difficult to feel part of the team when on the disabled list. Because of back problems, he didn't play a single Cactus League game during spring training. And he's spent more time during the first two weeks of the season on the road during an injury rehab assignment with Stockton and Sacramento than he'd spent with the A's before flying in to join the club Thursday in Minnesota.
``I thought I was being put on the roster then, to be honest,'' Gentry said. ``Why it didn't happen, I don't know. But it's happened now, and I'm happy about it.''
Gentry wasn't in the starting lineup Saturday and doesn't figure to start Sunday as the series wraps up against Seattle, but manager Bob Melvin said Gentry will probably get two starts in the three-game set that begins Monday in Anaheim.
Fuld, meanwhile, is probably lost to the A's, who under baseball rules have 10 days to trade him, release him or put him on the minor league roster if he clears waivers. Nothing is ever certain, but it defies logic that at least one of the other 29 teams wouldn't make a stab at Fuld, a player the A's hate to give up.
``It's absolutely a difficult decision,'' Melvin said. ``In a short period of time here he has impacted some games for us. He's been right in the middle of some wins. Whether or not we get a chance to have him back here or not, he has contributed in a short period of time.''
Melvin said that with Coco Crisp now healthy and in the lineup after missing four games following a cortisone shot and Gentry set as the fourth outfielder, the A's outfield was too crowded to think Fuld would get much playing time.
``We do have Brandon Moss who can play the outfield too,'' the manager said. ``Barring some injuries, and you can never really forecast that (there wasn't a need for Fuld). It was a tough decision. We wish him the best. He's a terrific person; he fit in well here. He implied to me he had fun here.''
Gentry, like Fuld, is a defensive whiz and counts high-percentage base stealing among his attributes. And while he won't start a game in Seattle this weekend, he could end one.
``He's a really good end-game player, pinch-hitting, base running,'' Melvin said. ``That's one of the reasons we targeted him.''
``He came to me after BP yesterday and said `I'm ready,' Melvin said. ``That's all I needed to hear from him. He is pretty aware of his body, he has played through some injuries, and he knows what is more serious than others. I rely on what he has to tell me and that feedback.''
Crisp had the cortisone injected last Sunday and the A's have been playing it by ear as to when he'd get back into the lineup. The original hope was for Thursday in Minnesota or Friday in Seattle, but the club wanted to make sure he was not going to be rushed.
``When you pitch at the end of the game, you're going to face the same hitters,'' he said. ``I'm not going to be doing anything any differently if I faced the middle of the lineup in the ninth inning than I would if I was facing them in the eighth.
And Gregerson doesn't expect Johnson, who pitched two scoreless innings Friday, to be out of the closer's job for long. Johnson had an 18.90 ERA after his first five appearances, two of them losses and one a blown save.
``Jimmy will be fine,'' he said. ``Obviously when you are with a new team you want to make a good first impression. But he's going to be all right. He was throwing that good curve for strikes and that gives him one more weapon.''
For more on the A's, see John Hickey's Inside the A's blog at ibabuzz.com/athletics. Follow him on Twitter at twitter.com/JHickey3.


text:
Colorectal Cancer Health Center
Latest Headlines
Up to 40% of people who should get a test for colon cancer aren't doing so.That's one of the reasons why some doctors are encouraged by Cologuard, a new at-home test for colon cancer.
Top Stories
Related WebMD Community
Message Boards
Top Search Terms for Colorectal Cancer
Understanding Colorectal Cancer -- Symptoms
What Are the Symptoms of Colorectal Cancer?
In its early stage, colorectal cancer usually produces no symptoms. The most likely warning signs include:
- Changes in bowel movements, including persistent constipation or diarrhea, a feeling of not being able to empty the bowel completely, an urgency to move the bowels, rectal cramping, or rectal bleeding
- Dark patches of blood in or on stool; or long, thin, "pencil stools"
- Abdominal discomfort or bloating
- Unexplained fatigue, loss of appetite, and/or weight loss
- Pelvic pain, which occurs at later stages of the disease
Today on WebMD
The right diagnosis is the most important factor.
Our health check will steer you in the right direction.
Fight cancer one plate at a time.
Colorectal Cancer Therapy


text:
Discover a selection of top forums halo undertaker on the internet. Come to share your passion on forums halo undertaker and meet other fans of halo undertaker. Then, why don't you create your own forum of halo undertaker ?
Has your Spartan got a story? Your Elite got a history? Share it here in our Halo database! Here you can post stories and create tales and vent your creativity of the Halo Universe!
True Talent was founded back in June of 2009 for one reason; to bring gamers together. Since then we have kept evolving and changing with the times to keep up with the gaming industry. We currently have a strong group of dedicated members that have k
Free forum : A forum meant for discussions of all sorts.
free, mystic, forum, games, anime, dragon, ball, inuyasha, fullmetal, alchemist, full, trigun, hellsing, bleach, final, emblem, call, duty, #halo, fantasy, fire, video, street, fighter
Free forum : Welcome to the Halo for pc's Burnt-Toast-Zooka Official Clan Forums!


text:
- Feb 11:
- Purdy: Olympic ski jump represents a giant leap for women
- Olympic stunner: Shaun White fails to medal in halfpipe
- Olympics: Randall out early in women's cross-country sprint
- Olympics: Carina Vogt wins 1st gold medal in ski jumping
- Olympics: Volosozhar-Trankov lead pairs after short program
- Who will replace Costas in Winter Olympics TV duty?
- Purdy: Sochi's snow problem is a big problem
- Purdy: Alex Ovechkin, Russian hockey team under huge pressure
- Sarah Burke inspired Olympic freeski movement
- Olympics: American Devin Logan wins silver in women's slopestyle skiing
Happy Tuesday.
Here's a recap of what happened overnight in Sochi and preview of the packed morning schedule.
American Devin Logan earned a surprising silver medal in the women's freestyle skiing slopestyle event.
Logan, a 20-year-old who's from Oceanside, scored 85.40 on her first run, then watched as only one skier beat that number: Canada's Dara Howell.
Keri Herman, projected to be the United State's top medal contender, finished 10th.
And in the women's cross country sprint, Kikkan Randall, considered the United States' top medal, was knocked out in the quarterfinals.
Sophie Caldwell finished sixth, the best ever in the sport for an American woman.
Early risers have a chance to track two early-morning events:
The women's 500-meter speed skating finals was scheduled to begin at 5:45, with former inline skater Heather Richardson as the top U.S. medal hope. She would be the first American woman to win the 500-meter long track since the great Bonnie Blair 20 years ago. The finals will be shown later today on NBCSN.
And at 7 a.m., the figure skating competition resumes with the pairs' short program. Russians Tatyana Volosozhar and Maksim Trankov are the reigning world champs and heavy favorites. NBCSN will show the event live.
Erin Hamlin is in third place entering the final day of competition in the women's luge singles. No American man or woman has ever medaled in the luge singles. The finals will begin at 8 a.m. (approximately), but there is no live broadcast.
ON TAP THIS MORNING II: Shaun White goes for gold
In a nutshell: White is attempting to become the first American man to win the same event at three consecutive Winter Olympics. White's competition includes Switzerland's Iouri Podladtchikov, better known as "I-Pod." The festivities get underway at 9:30 a.m. (approximately), but don't look for a live broadcast — this is a primetime event all the way.
ON TAP THIS MORNING III: a soaring start
Women's ski jumping makes its Olympic debut. The American to watch is 19-year-old Sarah Hendrickson of Park City, Utah. All of 95 pounds (on a 5-foot-4 frame), Hendrickson tore ligaments in her knee in August but was named to the U.S anyhow — she's that good. The event will be shown live at 10:15 a.m. on NBCSN.
Want it live? Get the APP
NBC and its family of networks will provide 1,539 hours of coverage, but the only place you can watch everything live is online.
The choice events will only be shown on TV on a delayed basis as part of NBC's prepackaged primetime broadcast. The only way to have access to everything live is on your digital devices through the NBC Sports Live Extra app.
It's free to download, but you'll need to be a cable or satellite subscriber in order to log-in. For more information, go to: http://www.nbcolympics.com/liveextra/help.


text:
Location: Vegetable Crops Research Unit
Project Number: 5090-21000-062-21
Start Date: May 28, 2012
End Date: Jul 31, 2016
a) Plant carrot seed with elite nematode and alternaria resistance and weed tolerance for testing in conventional and organic fields, three replicates each entry. b) Evaluate seedling emergence. c) Hand weed organic plots as needed; control weeds in conventional trials. d) Evaluate top size of each entry at one month, three months, and harvest. e) Harvest crop and provide root samples to PI's lab.


text:
The New School
Spring 2013 Ensemble and Recital Series: Stephen Nelson, guitar
New School Jazz student Stephen Nelson (guitar) presents his senior recital.
First GroupSteve Nelson - GuitarDevin Starks - BassBram De Lootz – PianoDrums - TBAPlaying my original music and standards.Second groupJAMSKI TRIOSteve Nelson – GuitarConor Syzmanksi – DrumsLuca Rosenfeld - BassWill play original music from our repertoire.
Steve Nelson is a unique Jazz guitarist. Since moving to New York in 2010 he has had the opportunity to play around New York through the gig office and through his own gigs. He has played smaller Jazz Clubs such as Somethin' Jazz, Tomi Jazz and Chris's jazz club, as well as taken part in festivals like Central Park's Jazz and Colors Festival. Steve has also played a lot of private events and wedding gigs. Steve is currently in his last year at the New School for Jazz. Through school he has had the privilege with studying with greats such as, Peter Bernstein, Juian Lage, Steve Cardenas, Andrew Cyrille, Reggie Workman, Vic Juris and many others. In high school Steve was a part of the All Southern California Jazz Band which got to perform at Disneyland. After high school Steve moved to Montana where he found solace in the nature. After a year off of dedicated practicing, he then attended the Cornish College of Arts in Seattle. He was awarded the Nellie Scholarship which is a merit scholarship given to few students. After playing around Seattle, Steve realized his future lay in New York. He has been working in New York ever since. Steve currently leads a Trio that plays weekly and performs original music. Steve hopes to keep playing with this band as well as pursing as many other opportunity as possible.
Jazz and Contemporary Music Performance Space, Arnhold Hall, 55 West 13th Street, 5th floor
Free; no tickets or reservations required; seating is first-come first-served
Email Updates
Browse Events by School


text:
Belgium, 2012, 98 Minute Running Time
Genre/Subjects: Drama, GLBT, Romance
Programs: Cinema Q, New Directors ShowcaseLanguage: French English Sub-Titles
Paulo is a piano player at an art house that shows silent movies. Ilir is a bartender originally from Albania. They're both good-lucking, and after some intense eye contact in the bar where Ilir works, they end up in bed together. Paulo is so drunk that nothing happens. And as Ilir points out, Paulo is really still in the process of figuring out his sexual orientation. He lives with Anka, a fashion designer, who knows his wily ways and his bisexual tendencies. When she can no longer stand his absences and secrets, she throws him out. He lands on the doorstep of his new friend and asks to be taken in. Ilir acquiesces, even though he knows it's too soon.
Commitment and permanence become issues on Ilir's side, and are interestingly portrayed in a sex scene. But the budding relationship hits a major obstacle when Ilir is busted for hash possession and sentenced to 18 months in prison. The beautiful, playful Ilir becomes something else, and despite Paulo's faithful visits and his patient love, the relationship can't go any further. Paulo finds solace in the arms of a middle-aged sex-shop owner who vows to take care of him, something the boyish young man could clearly use. When Ilir is released from prison, he seeks out Paulo in the hope of reigniting their passion.
Following in the footsteps of Weekend and Keep the Lights On, Belgian writer-director David Lambert tells this story of the flowering and dissolution of a gay love affair with a sweet melancholy. Beyond the Walls is Lambert's debut feature film.
Click here for Information on Group Rates
Sponsored by:
DIRECTOR: David Lambert
Producer: Jean-Yves Roubin, Daniel MorinEditor: Helene GirardScreenwriter: David LambertCinematographer: Matthieu Poirot DelpechPrincipal Cast: Matila Malliarakis, Guillaume Gouix, Melissa Desormeaux Poulin, David Salles
CLICK IMAGE for the Member Newsletter
CLICK IMAGE to submit to the Denver Film Festival. Withoutabox logos are trademarks of Withoutabox, a DBA of IMDb.com Inc. or its affiliates.
CLICK IMAGE to Renew or JoinMembership Updates and Sign Up
CLICK IMAGE for Information
CLICK IMAGE for more information
Site powered by: Luminate


text:
Log in
R.I.P. - please do not politicize this
View previous topic
View next topic
Strange Famous Forum
Hall of Fame
Joined: 01 Jul 2002
Posts: 10924
R.I.P. - please do not politicize this
This just a quick R.I.P. for those who have died in the past couple days regardless of race, religion or country of origin.
Sound off if it's been on your mind. If it hasn't, don't feel bad - just don't post.
No political arguments, please.
- Shane
Mon Mar 24, 2003 3:55 pm
Sage Francis
Self Fighteous
Joined: 30 Jun 2002
Posts: 21790
Mon Mar 24, 2003 4:59 pm
Joined: 05 Jul 2002
Posts: 807
Mon Mar 24, 2003 5:05 pm
Joined: 27 Sep 2002
Posts: 3990
Location: Montreal
"In the end the first shall be last and the last shall be first." - Justice is swift.
Mon Mar 24, 2003 5:07 pm
eggplant xanadu
Joined: 10 Oct 2002
Posts: 2946
Location: Boston
Mon Mar 24, 2003 5:07 pm
Joined: 01 Jul 2002
Posts: 628
Location: asheville, NC and NYC
RIP to every single person.
Mon Mar 24, 2003 5:39 pm
Joined: 25 Aug 2002
Posts: 9309
Mon Mar 24, 2003 5:41 pm
cutie n3wb
Joined: 30 Jun 2002
Posts: 523
Location: lake charles, la
Mon Mar 24, 2003 6:14 pm
Joined: 20 Nov 2002
Posts: 155
Location: NYC - Via Canada
Mon Mar 24, 2003 6:18 pm
tom inhaler
me too!
Joined: 30 Jun 2002
Posts: 4397
Location: providence
Re: R.I.P. - please do not politicize this
rest in peace.
Mon Mar 24, 2003 6:43 pm
Joined: 02 Nov 2002
Posts: 595
rest in the peace.
moments of silence.
Mon Mar 24, 2003 7:11 pm
Joined: 02 Jul 2002
Posts: 6165
Location: privileged homeless
It's kind of redundant, isn't it?
They're resting in peace. They're dead.
If I spend sixty seconds staring at my shoes, it won't help anyone to rest any more peacefully.
I'd like to propose an alternative to the traditional moment of silence. I'd like to propose SCREAMING UNTIL YOUR THROAT BLEEDS for every life lost.
What's so great about silence? Fuck resting in peace. I don't want people resting in peace. I want people roiling in conflict, jostling, interacting and wrestling. I want them running, fighting, anything but resting.
Peace is the carrot dangled. Peace is the light at the end of the tunnel.
Peace is death. I don't want people dead. None of them. Not Iraqis, not US Marines, not Kurds not Israelis not Afghanis not the French the British nor the Russians. Not the Ethiopians not the Cuban dissidents and not the Cuban establishment. Not the Palestinians in Gaza and not the Neoconservative hawks in Washington. Not George W Bush not Saddam Hussein not Donald Rumsfeld not Osama bin Laden not Jacques Chirac not Vladmir Putin not Jesus Christ nor Judas Iscariot.
I want them all alive, at the very least.
Fuck resting in peace.
(I'm sorry if this is taken as "politicizing". The only thing I'm trying to say is I hate anyone being dead, and I feel like that is in tune with the thread's intent, even if I'm challenging the language)
Mon Mar 24, 2003 8:18 pm
Joined: 17 Feb 2003
Posts: 187
Location: worldwideweb of lies
jesse-i agree with pretty much everything you said..
but if im not mistaken arent you the very person that attacked sole for screwing up buck65s manoverboard album..you at that time didnt let i rest till you caught heat for posting that ish..so i see a time for a moment of silence for the dead to be a good thing because if all were alive and at home some would have been catching heat or screaming out loud having sex or what ever for that matter..so im not trying to bust your balls but...im going to say.....rest in peace
Mon Mar 24, 2003 8:30 pm
gerhupsom vanbone
Joined: 03 Jul 2002
Posts: 2697
Mon Mar 24, 2003 8:48 pm
Joined: 02 Jul 2002
Posts: 6165
Location: privileged homeless
um it's not really worth a new thread but I don't want to clutter up this one,
so off we go, you and I, agent00f
Last edited by Jesse on Mon Mar 24, 2003 9:05 pm; edited 1 time in total
Mon Mar 24, 2003 8:52 pm
Jump to:
Select a forum
Strange Famous BBS
The General Forum
SFR Artists, Albums & Merch!
Hall of Fame
Social stuff. Political stuff. KNOWMORE
IF YOU WANT TO JOIN THE FORUM, READ THIS 1st
Old Shows. Come meet the ghost of performance past.
Goto page
All times are GMT - 6 Hours.
The time now is Tue Aug 30, 2016 6:30 pm
Display posts from previous:
All Posts
1 Day
7 Days
2 Weeks
1 Month
3 Months
6 Months
1 Year
Oldest First
Newest First
Powered by phpBB: © 2001
phpBB Group
Template created by
The Fathom
Based on template of
Nick Mahon


text:
I've spent time this month in a world with no TV, car or smartphone -- let alone a nice glass of pinot with a dinner that, with Trader Joe's help, took me 15 minutes to prepare.
It's the world created by Edan Lepucki in "California," yet another depiction of a dystopic future, in this case in the form of a novel that's set a couple of generations down the road after society has broken down over the chasm between the haves and have-nots. The protagonists, a young couple named Frida and Cal, have used their last money and gas to flee Los Angeles and head north -- how far, we have no idea -- where they are surviving off the land. They're hungry, unwashed, fearful, bored, and with simple dreams like getting their hands on any number of creature comforts they vaguely remember from a much earlier life, be it a bar of Dove soap or a book.
It's a miserable existence as imagined by Lepucki, whom many will recognize as the Bay Area writer who won the literary lottery this summer when her debut novel was singled out by Stephen Colbert as part of a high-profile feud between his publisher, Hachette Book Group, and Amazon over the price and release of e-books.
On his late-night Comedy Central "faux news" program, Colbert made a passionate plea to viewers to stand behind independent bookstores and make a statement by buying her soon-to-be released "California" from Powell's Books in Portland, Oregon. My husband, who never passes up an excuse to help keep a bookstore, author or public library afloat, went online and put in an order at Powell's the very next day.
Reading "California," I found myself once again appreciating the pleasures of a warm shower while wondering if Frida and Cal were anywhere near Eva and Nell, two teenage sisters struggling to survive in their rural, isolated home somewhere in rural Marin County in an eerily similar book, "Into the Forest," by Jean Hegland, which I remember vividly, maybe because I was so captivated I read it twice.
As is the case with "California," the hows and whys of the societal breakdown in Hegland's book were vague and ominously topical -- natural resource shortages, foreign conflicts, newspapers no longer showing up on the doorstep.
I don't know exactly where "Into the Forest," published in 1996, fits into the timeline of such fictions -- it was long after the "Mad Max" movies, but it preceded Cormac McCarthy's disturbingly violent "The Road," and the uber-popular "The Hunger Games" and "Divergent" series. All I remember is that Hegland's rich depiction of a world that's coming apart at the seams had me spellbound, terrified and viscerally appreciative of the fullness, richness and basic comforts of my day-to-day life.
Not that it was a particularly charmed or easy life, but I had a car with gas in the tank, a nearby grocery store and was about to marry a man who could cook and make me laugh. We also had shelves lined with books, a TV with basic cable, a CD player, even a computer, which back then was just a nice thing to have, not the umbilical tether it's become today. But more important, we had electricity and hot water from the tap anytime we needed to do the dishes.
At the time I was reminded of a few favorite books from childhood and I realized then the connection was perspective they gave a kid bored out of her mind in the summer heat of suburban Tucson, Arizona. Thanks to weekly trips to the public library, I at some point realized things could be worse -- if I had been born 100 years earlier, I might be carrying a baby sister in my arms as I staggered along the Oregon Trail with what was left of my family in Mary Jane Carr's "Children of the Covered Wagon," or freezing to death on a prairie in Laura Ingalls Wilder's "The Long Winter."
Escape, empathy, the excuse to get together with a book group for lively discussions with friends are just three things we get out of reading good books. The fourth is perspective, which turns out to be a fabulous coping mechanism. Anytime you're having a bad day, all you need to do is take a deep breath and remind yourself you're not a jailed immigrant facing deportment to Nigeria ("Little Bee") or a woman of any color, but especially African descent, living in South Carolina during slavery ("The Invention of Wings") or a mother forced to choose between which child lives and which one boards the train to certain death at a Nazi prison camp ("Sophie's Choice").
If we let it, literature can help remind us how fortunate we are just to have the luxury of sitting there reading a good book, be it on an iPad, a Kindle or in print. With that in mind, I'm going to start tapping my own imagination not to write another dystopic fiction -- there are plenty of those already -- but to start plotting a safe place to hide our favorite hardbacks and paperbacks, maybe stockpile some extra reading glasses just to be safe.
This summer's news -- water shortages, conflicts on foreign soils, the growing chasm between the haves and have-nots -- makes it feel like we might just be heading into the forest sooner than later.
And just as fiction about the past makes us appreciate the present, books such as "California" remind us to never take the pleasures of our current lives -- imperfect though they may be -- for granted.
Lisa Wrenn is executive features editor for the Bay Area News Group. Follow her at Twitter.com/lwrenn.


text:
Comprehensive DescriptionRead full entry
BiologyLength type is height (=TL - head length). Found in seagrass beds. Ovoviviparous (Ref. 205). The male carries the eggs in a brood pouch which is found under the tail (Ref. 205).
Species recognized by Integrated Taxonomic Information System (ITIS) • Remove classification filter
Hippocampus borboniensis Unreviewed
Wikimedia Commons
Solenostomus cyanopterus Unreviewed • Anguilla Unreviewed • Hippocampus borboniensis Unreviewed ... more taxon associations
text: Alfred Grandidier (1836-1921) artists: various (Arnoul)
Wikimedia Commons
729669 other items
326476 other items
1240647 other items
This taxon hasn't been featured in any communities yet.
EOL content is automatically assembled from many different content providers. As a result, from time to time you may find pages on EOL that are confusing.
To request an improvement, please leave a comment on the page. Thank you!
Become part of the EOL community!
Already a member? Sign in


text:
If you want to create a super-special cake, but think you don't have the skill, think again. We'll make you a pastry chef in no time.
Weekdays on Nick Jr.
Preheat the oven to 350°F. Grease and flour an 8-inch-round and an 8-inch-square cake pan. Prepare the cake mix according to package directions. Fold the mini chips into the cake mix. Divide the batter evenly between the prepared cake pans. Bake the cakes until golden and a toothpick inserted in the center comes out clean, about 35 to 40 minutes. Transfer the pans to a wire rack. Cool for ten minutes; then invert and cool the cakes completely.
In the meantime, unwrap yellow fruit chews and heat them in the microwave for five seconds to soften. Roll together all but one piece, making a 4- by 7-inch rectangle. This will be Map. Cut the remaining piece in half diagonally for Backpack's eyebrows and set it aside.
Make eyes by cutting the white taffy into two sizes, 1 1/2 inches and 3/4 inch. Cut the red taffy into a 3-inch crescent and a 1-inch triangle for Backpack's and Map's mouths. Set aside.
Spoon two teaspoons of the white frosting into a resealable plastic bag and set it aside. Divide the remaining frosting into thirds. Tint each bowl a different shade of purple; from light to dark. Spoon the darkest purple into a resealable plastic bag.
Cut the round cake in half, making two semicircles. Cut out a 2 1/2-inch-wide strip from the square cake. Place the large cake rectangle in the center of a cake platter so the long sides are at the top and bottom. Place one semicircle on either long side of the rectangle with their cut sides facing in. The top semicircle should overhang the right side of the rectangle by 1 1/2 inches. The bottom semicircle should overhang to the left by 1 1/2 inches.
Using a bit of the medium-purple frosting, attach the two cream-filled cakes along the left side of the cake. Make Map by rolling the yellow candy rectangle around the top snack cake, letting some overhang at the top.
Cut the leftover rectangle of cake into a 4-inch and a 2-inch piece. Place the smaller piece at the top of the cake so it fills in the gap between Backpack and Map and helps support Map. Place the longer rectangle at an angle by the upper-left corner of the cake, to make the shoulder strap. Trim the pieces slightly to round the cake's corners.
Using the photo above for reference, frost the part of the cake that will be Backpack's face with the lightest purple frosting. Frost the snack cakes, Backpack's top, the shoulder strap, and the sides of the entire cake with the medium-purple frosting. Snip a small corner from the bag of dark-purple frosting and pipe along the sides of the cake using a top-to-bottom, zigzagging motion.
Trim and attach the licorice as a strap. Place the eyes, eyebrows, and mouths on the cake and on Map. Use the candy-coated chocolates as the center of the eyes. Spoon chocolate frosting into a resealable plastic bag. Pipe chocolate lines around the eyes, mouths, and around Map use chocolate frosting to write a birthday greeting.
Dora takes the cake. And in this case, she IS the cake!
Get a taste of the tropics with this healthy, fruity drink!
Thanksgiving guests will want to swipe every last piece
Make this a-DORA-ble autumn treat for the apple of your eye!
Kids will go bananas for Boots' yummy baked treat!
Turn breakfast into an adventure when you make Dora pancakes!
Present your pie with your preschooler's favorite explorer!
Dress up sugar cookies in Dora's festive and fruity attire!
Bake up purr-fect cookies for your Halloween fiesta!
Make this a-DORA-ble sandwich for your sweetheart!
Charm loved ones with Dora's dainty cupcake rings on Valentine's Day!
Warm their hearts with Dora's favorite drink!
Kids will get a kick out of making Boots from bread and bologna!
You'll be a star in your preschooler's eyes when you make these stellar yet easy treats!
Bake up Boots with your little kitchen helper!
Your little star will love exploring this healthy pasta salad!
Share this snack with your little explorers. They're sure to swipe it right off the kitchen table!
Make a cake fit for a princess!
The ice-cold treat is just right for quenching an explorer's thirst.
A homemade holiday tradition with a delicious Dora twist!
Summon a sea filled with sweet starfish covered in icing
Treasure the smiles when you make these cupcakes for your little pirate!
A royal recipe with a sweet surprise!
Ahoy! It's Dora in her pirate gear
Kids of all ages will swipe these cupcakes faster than you know who!
Dora on a cupcake? Delicioso!
Dora takes the cake. And in this case, she IS the cake!
Bake up a perfect party cake for your Peppa fan!
On a mission for an umirrific cake? It's Bot to the rescue!
Bake a cake to look just like your kid's favorite pattern-powered Umi friend!
Shape a cake to look like Geo!
Bake the cake and top it off with Molly and Gil!
Turn plain pound cake into bite-sized cake pops that look like Little Fish!
Here's a fresh cake that will take center stage at your next party!
Take your little Umizoomi fan for a sweet ride with this easy homemade cake
A simple sheet cake gets the royal treatment with frosting & fruit chews!
Bake up Boots with your little kitchen helper!
Make a cake fit for a princess!
Invite Jack to your child's birthday party
Boutique baker? Make it look that way with our template
A royal recipe with a sweet surprise!
Want a clue about what to serve at the next birthday party?
Making Pablo is a piece of cake
It's a cake of everyone's favorite DJ, DJ Lance Rock!


text:
Click here for the 2015-2016 Meeting Schedule
Marc Newman(Vice Chair) Managing Partner,
Margaret T. Coffey (Chair)Program Manager/Teacher, Binghamton City Schools (retired)
George F. Akel, Jr. President, Akel Wholesale
Naima Kradjian CEO and executive director of Goodwill Theatre Inc.
Anthony Paniccia President & CEO of Delta Engineers, Architects, & Land Surveyors, P.C.
Dr. Angelo Mastrangelo Professor, Binghamton University
James Orband, Esq. Managing Partner,
Nicholas G. Serafini, Jr. Presiding Member, Serafini Auto Group
Nancy LaBare Former SUNY Broome Counselor and Interim Vice President for Student Affairs (retired)
Thomas Flynn SUNY Broome Student Trustee
All meeting sites are on the SUNY Broome Campus and the
meetings are open to the Press and Public
BOT 2015 - 2016 Meeting Schedule


text:
Share Photo
Martin Evans surveys the damge to his roof-less house on in northeast Raleigh, N.C. on Tuesday, April 19, 2011. Cleanup was on going as the whole neighborhood was littered and homes damaged with trees felled from Saturday's tornado. From remote rural communities to the state's second-largest city, thousands of residents hit by the most active tornado outbreak recorded in North Carolina's history were clearing away rubble and debris, repairing power lines and facing a recovery that will cost tens of millions of dollars. Gov. Beverly Perdue on Tuesday requested a federal disaster declaration for 18 counties, which would open up federal aid. (AP Photo/The News & Observer, Chris Seward) MANDATORY CREDIT


text:
Are your lenses as clean as they should be?
July 26, 2012 Leave a comment
A recent study in the December 2011 Journal of Optometry and Vision Science has shown that while 85% of contact lens wearers believe they do a good job taking care of their contact lenses, in actuality, less than 2% of them properly care for their lenses. .
Results show that some of the biggest non-compliance issues are:
- Replacing lenses infrequently and wearing them longer than the recommended time frame
- Sleeping in their lenses
- Exposing their lenses to water when showering, swimming or rinsing lenses in tap water
- Not emptying out their lens case/topping off with solution
- Changing their lens case infrequently
- Not properly washing their hands before handling their lenses
Non-compliance can cause issues beyond simple lens discomfort, including conjunctivitis, also known as "pink eye," getting a sty on the eyelid or more serious compilations such as E-Coli due to the bacteria growing in their lenses and cases.
The study also shows that while most wearers are aware of proper lens care practices, very few actually follow through resulting in 72% of patients experiencing complications with comfort and 19% experiencing some type of infection. .
What can you do to prevent issues?
- Make sure to wash your hands with warm water and soap before handling your lenses and touching your eye.
- Wear a fresh pair of lenses at the recommended time, i.e. daily, every two weeks or monthly as suggested by your eye doctor.
- Remove your lenses before showering or going swimming, or wear proper fitting eye goggles that prevent water from entering the eye.
- Do not sleep or nap in your lenses.
- Clean your lenses every night with contact lens solution and use fresh solution in your lens case every night. Don't use water or top off the solution in your case, mixing old solution with new.
- Rinse your lenses in solution before inserting them.
- Rinse your lens case with solution daily and allow it to air dry while not in use.
- Replace your lens case every few months. Many lens solutions come with a case in the box, so replacing your lens solution is a good time to throw out the old case and start fres


text:
If You Give a Kid a Spatula …
I hope my kids learn to cook. And love to it as much as I do.
I truly believe that one of the greatest gifts we can give our children is an appreciation for food. And by food, I mean real food — food that doesn't come out of a can or microwaveable container. This hope is not just for my children; I hope more and more kids everywhere grow up with a renewed understanding of where food comes from and a respect for the plants and animals they eat.
Instead of citing studies about the rise of childhood obesity and rambling on about why teaching our kids to cook will make the world a better place, I've written a hopeful little story (with respectful credit due to Laura Joffe Numeroff and Felicia Bond, authors of many beloved children's books, including, of course, If You Give a Mouse a Cookie). I hope you like it.


text:
Super Mario Galaxy sets an incredibly high bar for other games that come out on the Wii, and I certainly hope that they are able to match it, because if they can, the Wii will be able to truly give the Xbox 360 and the PS3 a run for their money when it comes to software.
Nintendo Wii
If you are a fan of Mario games or have ever played a Mario game then this game will simply meet your expectations on that basis alone. There is really a ton of gameplay and fun packed into this game. I actually picked up this game a week ago and haven't put it down since.
First of all the graphics are all 3D and incredible. It has a sequel feel to from the great Mario 64, that we all came to love over the years. You will first notice that when you start out you are on a ship and there are different areas (levels) you can go into. There are variety of rooms in which you can travel to new galaxies. Most will have a boss scene at the end.
Without ruining the storyline and everything I will sum it all up in one sentence. Once again, you do have to rescue Peach from Bowser as it most Mario games. You are going to be traveling to galaxies (about 40 in all). All kinds of exciting gameplay which could be anything from going around on land dodging boulders, swimming, and even underwater. There are also ice levels, lava levels, and mechanical machine levels, as well.
You are going to be traveling around a lot and collecting stars (about 120). The gameplay is really fun and pretty simple. You are going to control Mario with the analog stick, but also point and interact, as well as throwing star bits. There are tons of characters and lots and lots of environments to explore.
The camera system is excellent and doesn't seem to get in the way at all. You can go left, right, up, down and the camera will just follow what you do. So many games that you play these days don't make an effective use of the camera, but Super Mario Galaxy simply writes the book on how a camera system should work.
I actually thought this was the new Wii Super Mario Galaxy 2, I didn't realize until I seen the advert that it wasn't the game I wanted, it does enable me though to now purchase the new Mario Galaxy 2 though so there's a bonus.
The lasting effect on this game is great. Best graphics, music, and gameplay, you can find on the Wii.. You will simply get your money's worth out of this game. This game will go down in the history books and simply stand the test of time.


text:
Trade Groups Take Stand to Protect Drug Supply
Trade Groups Take Stand to Protect Drug Supply
01.31.13 | By Mark Grayson
The National Conference of Pharmaceutical Organizations (NCPO) highlighted important issues to keep the supply of medicines safe in the United States. According to Lucinda Maine, Executive Vice President and CEO of the American Association of Colleges of Pharmacy, " Pharmacists are taught that medication safety is their highest professional priority. The integrity of the distribution system is essential in the fulfillment of this mission."
Among the issues that NCPO discussed were the characteristics of an electronic system to trace prescription medicines in the supply chain. To read more about NCPO and its recommendations, look here.


text:
Prostate Cancer, and how we can help.
If you've been diagnosed with prostate cancer or told you're at high risk for it, you're probably facing many decisions — choices that can be overwhelming and hard. At Memorial Sloan Kettering Cancer Center, we too are constantly thinking of those questions — and how we can be the answer to all of them. Our experts know that personalized treatment is key to giving you the best outcome and quality of life possible.


text:
Calendar of events
Events for Today:
Experience the beauty of the Arboretum's 1,700 acres on a guided tram tour. April 25, 2016 through November 6, 2016 (except July 22 and 29), weather permitting.
Enjoy creative, unstructured outdoor play at our new Mud Kitchen near Parking Lot 20.
Discover 19 displays with 23 larger-than-life copper frog sculptures located along the paths within walking distance of the Visitor Center. Friday, April 8 through Sunday, September 25 at The Morton Arboretum.
Unwind after work with live music and drinks on warm summer evenings in Arbor Court. Wednesdays, June 1 through September 7, 2016 from 5:30 to 8 p.m.Wednesday is the new Friday!
Explore nine miles of paved roads that wind through our magnificent tree collections. Daily, May 30 - September 5, 2016. Saturdays and Sundays, September 10 - October 30, 2016. 10:00 a.m.-4:00 p.m.
Come learn about the gifts that the world's endangered trees give us—and how you can join the Arboretum in saving them. Daily, 7:00 a.m. - sunset


text:
Anonymous: The RX-v4600 is part of the last Yamaha generation not to incorporate a dedicated iPod dock port. Of course you can use any generic one with analogue RCA terminals, but there will be no menu control through the receiver Mar 15, 12
Anonymous: Ensure you are www.esoccerpro.com out with the latest Nike football boots, from the Mercurial, T90, Tiempo or CTR360 range.Nike MERCURIAL Vapor - The Mercurial range offers lightweight products for those who want to be first to the ball.Nike T90 Laser - The Total 90 range is for the all rounder looking for power and precision.Nike CTR360 Maestri - The CTR360 range is for the master who controls the game and drives the team forward.Shop for your football boots from our top brands. We have all the football boots your favourite players wear with the latest adidas adipure, adidas F50 adizero TRX and adidas Predator boot ranges Mar 17, 12
Run an online store?
Use ProductWiki Connect for Merchants to enhance your product page and improve conversions.
ProductWiki Inc. © 2013. All rights reserved. ver: 4.1.6
Powered by Bootic Inc.
Privacy Policy | Terms of Use
SubscribeFollow Us
Get the free iPhone App!
Don't have an account yet? Create one!
Already have an account? Log In
Login normally by cancelling.
Enter the e-mail address you used to register with the site and we'll send you a new password.
We've noticed that you've made a few contributions, but haven't yet created an account.
Click here to register for an account.
Benefits of registering:
If you would like to continue without an account, just close this box and it won't reappear.


text:
Juventus slideshow
Premier League: Schweinsteiger has no 'personal problems' with Mourinho
Germany captain Bastian Schweinsteiger says he still dreams of playing for Manchester United and has not fallen out with Jose Mourinho. More »Omnisport - 4 hours ago
The transfer window: Bringing out the worst in people since 2002
Andrew Gaffney on how the final few days of the transfer window became a dangerous place on social media. More »Andrew Gaffney - 5 hours ago
Football: Alcacer, Hart, Wilshere and the deadline-beating deals still to come
Clubs across Europe have just a matter of hours to complete their transfer business for the next four months, we look at deals to be done. More »Omnisport - 4 hours ago
Football: Interview - "England don't need guys who think they should be there because of who they are" - Michail Antonio
The West Ham wideman was named in Sam Allardyces first Three Lions squad on Saturday evening, and told FFTs Ben Welch this summer why he believes hes right for the job More »FourFourTwo - 5 hours ago
Social Chatter: England fans baffled as Ross Barkley and Mark Noble are overlooked by Sam Allardyce
James Matthews rounds up the reaction to Sam Allardyce's first England squad as fans are baffled by the omission of two midfielders. More »James Matthews - 22 hours ago


text:
Japanese developers have dominated the first few weeks of the year. "Anarchy Reigns" and "Ni No Kuni: Wrath of the White Witch" are some of the better games of early 2013. Making up for the dearth of quality Japanese titles last year, that streak extends further with "Fire Emblem: Awakening."
The turn-based strategy game has been a staple on Nintendo systems, and its heroes have even shown up in the popular "Super Smash Bros." fighting games. But for some reason, many gamers haven't played what's arguably one of the better franchises out there.
"Awakening" is the series' first foray on the Nintendo 3DS, and it's a great entry point for novices. It lets players create their own male or female protagonist, who ends up being the tactician for the halidom of Ylisse. After a vague beginning, players see their hero regaining consciousness. Unfortunately, the protagonist is also suffering from amnesia and doesn't know where she came from.
Over the course of the campaign, players will discover what led to that strange prologue, as they help Chrom, the main character, battle against Plegia, a rival nation, other invaders and an ancient evil. They'll meet new allies along the way and help mold the company into an elite fighting unit.
But that's easier said than done. "Awakening" will take some time to learn, and it plays almost like an advanced form of chess as players enter battles having to choose which units to bring and where to place them on the battlefield.
From there, it's about outmaneuvering the competing army. To aid with that, there are several techniques at hand. Players can combine units to make them more powerful. They can also place them side by side so units can aid each other on the battlefield.
There are other factors to consider in a fight though. "Fire Emblem" has a rock-paper-scissors system with its combat where axes defeat spears and spears dominate swords while swords destroy axes. Some units have an inherent weakness compared to others. For example, bows and arrows will take down Wyvern riders. Players also have to juggle relationships among their squad.
As certain characters interact, they'll nurture a natural affinity. That translates into stat boosts when two units are next to each other. One character may even sacrifice himself to defend another. If that weren't enough, those friendships can ultimately culminate in marriage and eventually children.
Yes, "Awakening" lets players see the fruits of their, uh, labors. Through a major plot point, gamers will see what comes out of those relationships that form during gameplay. It's interesting to see the combinations that can come between a warrior and a mage or a pegasus knight and cavalier.
To actually create that dream pairing though, players will have to manage their troops carefully, because, like other entries, "Awakening" has permadeath. If characters die in battle, they'll be gone from the campaign, and that demise is surprisingly devastating. The developer, Intelligent System, does a good job of creating characters that players bond with. They'll want to see Lissa get together with Donnel or see Frederick and Sumia turn into a couple.
Players get to see these interactions in the barracks or scripted events, but sadly, not all the dialogue works for the characters. Sometimes, lines are repeated in nonsensical ways. Elsewhere, the visuals of the game board itself are unimpressive, but when it focuses on skirmishes between characters, the art showing the hand-to-hand combat is beautiful. That and the animated cutscenes nearly make up for a pedestrian interface.
"Awakening" has that one-more-turn quality that's inherent to many strategy games. It's an addictive formula that, combined with a plot that has several twists and turns, will keep players through a campaign that will last awhile. The only element holding it back is its difficulty. This game is hard, and it requires clever maneuvering or some grinding to reach the end.
Contact Gieson Cacho at 510-735-7076 or email@example.com. Read his blog at http://blogs.mercurynews.com/aei.
'fire emblem: awakening'
* * *
Platform: Nintendo 3DS
Rating: Teen


text:
FALL RIVER — A crowd packed the Eagle Event Center Sunday night to catch a glipse of Senator-elect Elizabeth Warren as she stopped by to thank supporters for choosing to send her to Washington, D.C., come January.
The Fall River visit was the last stop on a short tour around the state to meet with supporters and make herself available to the public. The tour included stops in Springfield and Worcester on Saturday and Fall River on Sunday, more will be announced in the near future, according to a statement from Warren's office.
"We're in this together and we've got to work together from the start," Warren said in a statement explaining the need for the tour. "We've got to help people get back to work, level the playing field for our small businesses and help middle class families get a fair shot to get ahead."
During her visit, Warren delivered brief remarks on the need for the Senate to change filibuster rules.
"If we operated on a strict majority rule ... imagine what bills would have passed," said Warren, who later said that the filibuster held up passage of three "jobs bills" and a number of judicial nominee confirmations.
Asked by reporters whether the impending fiscal cliff of automatic spending cuts and tax increases could be avoided, Warren said, "I sure hope so," and said she believed both parties could find "room for compromise."
"We can build a better future for our kids and grand kids," she said.
Location, ST | website.com


text:
Foodfacts.com looks into what's really in Snapple "Apple." Many consumers and bloggers recently took notice that "Snapple Apple" contains zero apples! Instead, this "apple" drink contains pear concentrate. Isn't this false advertising? The Consumerist recently reached out to Snapple in regards to this matter to receive the following e-mail back:
"Thank you for contacting our Company regarding our ingredients in our products.
Our Company complies with all applicable labeling regulations promulgated in the United States by the Food and Drug Administration and other regulatory bodies. Product flavor components that form part of our "natural" or "natural and/or artificial flavors" ingredients are considered proprietary to our Company.
If you have a concern regarding the intake of this product, we suggest that you contact your health care provider. If you have known sensitivities to any substance listed in the ingredient statement, we advise discontinuing use of the product.
Thanks again for contacting us.
Consumer Relations"
So why doesn't Snapple Apple use actual apple juice in their "apple" drink? The Consumerist points out that a real apple apparently doesn't provide the same "apple" taste some people expect. However, pears are somehow able to provide the "true apple flavor."
Apples score very high at Food Facts! They provide plenty of dietary fiber, vitamin C, and lutein, (an antioxidant which promotes eye health in preventing macular degeneration, light sensitivity, and cataracts.) Snapple Apple is missing out.
Next time you're looking for an apple juice or any type fruit juice, make sure to look for "100% pure" or "100% fruit juice" to get all the nutrients of the fruit or vegetable.


text:
Santa Clara County is once again calling out its board president, George Shirakawa Jr., for stretching the definition of prudent use of public funds -- this time allowing his staff to make donations to his personal choice of charitable causes, buying two $4,000 bicycles and feeding themselves at local restaurants despite prohibitions on such expenses.
In the second of two critical audits released this month, the county's finance agency announced Wednesday that based on his spending of public funds during four years in office, Shirakawa must "immediately reimburse" thousands more dollars than he had previously been called upon to return.
"I continue to be very disappointed in Supervisor Shirakawa's behavior," said Supervisor Ken Yeager, who in January will take over as board president. "I am still looking for an explanation from him on how this happened."
The county's Finance Agency reports that between 2009 and 2012, Shirakawa's office spent $30,040 on "donations and sponsorships" that in some cases clearly violated county policies and lacked the proper documentation. Other cases fell into a more murky area, with auditors backing off from describing the charges as a blatant policy violation, but expressing their discomfort with the spending.
Vinod Sharma, the Finance Agency director, reported that Shirakawa's office used funds designed for goods and services that "should not have been used for making donations." His reports states that in at least seven of nine instances, donations totalling $6,250 "were clearly in violation" of county policy. The "prohibited donations" to community groups and events -- while notably worthy causes -- were not given the OK by Shirakawa's four board colleagues, and left the spending entirely to his discretion.
The donations included everything from a $2,500 sponsorship of the San Jose Salsa Festival in 2009 to a $750 payment in September for youth lessons at the Sparkle Swim School.
"The county should be immediately reimbursed for these expenses," the report states.
In response to the audit, Shirakawa is taking issue with some of the findings, particularly those requiring him to repay the community donations. He continues to disagree that he should repay the nine donations totalling $8,790, which includes $4,500 county auditors flagged as inappropriate uses of his personal county credit card.
The earlier audit found that Shirakawa used his taxpayer-funded credit card to pay for his personal expenses and for items "strictly prohibited" and demanded the District 2 supervisor "immediately reimburse" $12,772.
The audits follow several reports in the media about Shirakawa's flagrant use of his "procurement card," designed for small-item purchases and county business-trip expenses.
Contact Karen de Sá at 408-920-5781 and Tracy Seipel at 408-275-0140.


text:
Locke takes announcer's snide quip caught on mic in stride
CONWAY — Jeff Locke has apparently gotten under the Cincinnati Reds' skin — or at least one of team's announcers. The All Star from Conway has allowed just one run and four hits in two starts against the Reds this season, but Sunday, while Locke was in the process of spinning a one-hit gem, Reds broadcaster Thom Brennaman was caught whispering, "This guy sucks."
Post a comment
You must sign in before you can post comments. If you are experiencing issues with your account please e-mail firstname.lastname@example.com.